Stephen Stahl, MD, PhD

Members of the International MAOI Expert Group discuss historical use of MAOIs, consider their efficacy and safety, and underscore the importance of reassessing their place in treatment algorithms.

Novel precision medicine tools in depression aim to identify the optimal treatment for each patient and have the potential to significantly improve depression management by guiding treatment selection for...

In patients with MDD with inadequate antidepressant response, adjunctive lumateperone 42 mg significantly improved depression symptoms and severity versus adjunctive placebo, and it was generally well tolerated.